A new financing will allow Knight Therapeutics (Knight Therapeutics Stock Quote Chart, News: TSX:GUD... Read More
Paradigm Capital analyst Christopher Lam likes the way Knight Therapeutics (Knight Therapeutics Stoc... Read More
A Health Canada request for more information means a delay is a slight negative for Knight Therapeut... Read More
A quarter that was essentially in-line with expectations isn’t changing Paradigm Capital analy... Read More
Today BioMarin (NASDAQ:BRMN) announced it had sold its FDA priority review voucher to Regeneron (NAS... Read More
Recent news that Halifax-based Immunovaccine (TSXV:IMV) was pulling its proposed public financing du... Read More
Investors are betting big on former Paladin Labs CEO Jonathan Goodman and his latest pharmaceutical ... Read More
Share
Tweet
pin
Share